Although infection rates following prostate biopsy have stabilized, the rates of emergency department visits and hospitalizations for post-biopsy infections are increasing, a study found.
In a study, natural killer cell activity (NKA) below 200 pg/mL predicted a nearly 5-fold greater risk of having a positive prostate biopsy compared with higher NKA values.
In a study, combining targeted and systematic biopsy detected 11% to 33% more prostate cancers than either method alone.
To investigate the risk of cardiovascular adverse effects associated with this antibiotic class, researchers conducted a systematic review, meta-analysis, and network meta-analysis using studies identified through a search of MEDLINE, EMBASE, and the Cochrane Library.
Study participants with acute urinary retention after TRUS-guided prostate biopsy were 4.5 times more likely to skip a recommended re-biopsy than men who had no initial biopsy-related complications.
Men on active surveillance for prostate cancer who had a negative confirmatory biopsy experienced an 88% decreased risk of progression to treatment.
In a meta-analysis, the risk of infectious complications was 78% lower with fosfomycin trometamol versus fluoroquinolones in men undergoing TRUS-guided prostate biopsy.
In a single center study, asymptomatic bacteriuria resolved before prostate biopsy, without additional treatment.
Multiparametric magnetic resonance imaging in conjunction with transrectal ultrasound-guided biopsy improves discrimination between clinically significant and insignificant prostate tumors and can spare patients unnecessary biopsies.
Rates of erectile dysfunction and urinary incontinence at 1, 2, and 3 years after radical surgery are not higher among men who have multiple prostate biopsies while on active surveillance for prostate cancer.
